Long Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Long Shen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Chenghua Xu
3 shared publications- Hong Wang
State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 shared publications Jinting Fan
3 shared publicationsLichun Kang
3 shared publicationsMingming Niu
3 shared publicationsNing Wang
3 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by KEAI Publishing in Fundamental Research
5-Hydroxyindirubin targets FLT3 signaling and synergizes with venetoclax in FLT3-ITD acute myeloid leukemia
- 1 March 2026
- Published by KEAI Publishing in Fundamental Research
Open Access5-Hydroxyindirubin targets FLT3 signaling and synergizes with venetoclax in FLT3-ITD acute myeloid leukemia
- 26 September 2025
- Published by Wiley in Interdisciplinary Medicine
- Vol. 3 (5)
Integration of CRISPR‐Cas9 Screens and Multi‐Omics Profiling Reveals CHD7‐ANGPT1 as a Novel Multidrug Resistance Axis in AML (5/2025)
- 26 September 2025
- Published by Wiley in Interdisciplinary Medicine
- Vol. 3 (5)
Integration of CRISPR‐Cas9 Screens and Multi‐Omics Profiling Reveals CHD7‐ANGPT1 as a Novel Multidrug Resistance Axis in AML (5/2025)
- Open Access
- 1 September 2025
- Published by Wiley in Interdisciplinary Medicine
- Vol. 3 (5)
Integration of CRISPR‐Cas9 screens and multi‐omics profiling reveals chromodomain helicase DNA binding protein 7‐angiopoietin‐1 as a novel multidrug resistance axis in acute myeloid leukemia
Acute myeloid leukemia (AML) is a devastating hematological malignancy and one of the most prevalent forms of leukemia in adults. Despite recent advancements and approval of novel targeted therapies, drug resistance remains a formidable clinical challenge. In this study, we conducted an unbiased CRISPR‐Cas9 knockout screen in AML cells to uncover novel mediators of resistance to the clinically approved FLT3 inhibitor gilteritinib. This screen identified chromodomain helicase DNA binding protein 7 (CHD7) as a new regulator of drug resistance. Strikingly, CHD7 loss not only conferred resistance to FLT3 inhibitors but also extended resistance to a broad range of therapeutics, including venetoclax and daunorubicin (DNR). Mechanistic investigations integrating transcriptomic and proteomic data revealed that CHD7 deletion upregulates angiopoietin‐1 (ANGPT1), which drives resistance by activating the PI3K/AKT and MAPK/ERK signaling pathways. Significantly, genetic knockdown of ANGPT1 or pharmacological inhibition of its receptor TIE2 partially restored drug sensitivity in CHD7‐deficient cells. Together, these findings identify the CHD7‐ANGPT1 axis as a novel mechanism of multi‐drug resistance in AML. Preclinical studies further suggest that combining targeted therapies with TIE2 inhibitors offers a promising strategy to overcome drug resistance in AML.
- 1 September 2025
- Published by Wiley in Interdisciplinary Medicine
- Vol. 3 (5)
Open AccessIntegration of CRISPR‐Cas9 screens and multi‐omics profiling reveals chromodomain helicase DNA binding protein 7‐angiopoietin‐1 as a novel multidrug resistance axis in acute myeloid leukemia
Acute myeloid leukemia (AML) is a devastating hematological malignancy and one of the most prevalent forms of leukemia in adults. Despite recent advancements and approval of novel targeted therapies, drug resistance remains a formidable clinical challenge. In this study, we conducted an unbiased CRISPR‐Cas9 knockout screen in AML cells to uncover novel mediators of resistance to the clinically approved FLT3 inhibitor gilteritinib. This screen identified chromodomain helicase DNA binding protein 7 (CHD7) as a new regulator of drug resistance. Strikingly, CHD7 loss not only conferred resistance to FLT3 inhibitors but also extended resistance to a broad range of therapeutics, including venetoclax and daunorubicin (DNR). Mechanistic investigations integrating transcriptomic and proteomic data revealed that CHD7 deletion upregulates angiopoietin‐1 (ANGPT1), which drives resistance by activating the PI3K/AKT and MAPK/ERK signaling pathways. Significantly, genetic knockdown of ANGPT1 or pharmacological inhibition of its receptor TIE2 partially restored drug sensitivity in CHD7‐deficient cells. Together, these findings identify the CHD7‐ANGPT1 axis as a novel mechanism of multi‐drug resistance in AML. Preclinical studies further suggest that combining targeted therapies with TIE2 inhibitors offers a promising strategy to overcome drug resistance in AML.
- Open Access
CAT-APP: Contamination Analysis and Tempering—An Automated Online Platform for Plasma Proteomics with Data Rescuing Capabilities
Plasma and serum proteome profiling have become central to biomarker discovery for medical research. The advent of high-throughput plasma proteomics pipelines has enabled the generation of massive datasets. However, biomarker discovery is frequently compromised by sample contamination, primarily from erythrocytes, platelets, and coagulation factors. Such contamination can lead to the false identification of contaminants as biomarkers in over 50% of studies or obscure genuine biomarkers due to contamination-induced variability. Currently, no tools are available to salvage such compromised data, and the default approach is often to discard the affected samples. To address this gap, we introduce CAT-APP ( C ontamination A nalysis and T empering-An A utomated Online Platform for P lasma P roteomics). CAT-APP tackles contamination through three key modules: multi-dimensional contamination assessment and adaptive contamination indexing, mathematical model-based contamination tempering, and data recovery evaluation with visualization. We applied CAT-APP to 28 independent plasma proteomics datasets and found that 82% exhibited contamination issues. CAT-APP markedly improved data quality by removing false-positive biomarkers introduced by contamination and restoring true biological signals that were previously obscured in representative datasets. To promote widespread adoption, we provide CAT-APP as an freely accessible, user-friendly, and robust web platform at https://www.bloodecosystem.com/tools/CAT-APP/ .
Open AccessCAT-APP: Contamination Analysis and Tempering—An Automated Online Platform for Plasma Proteomics with Data Rescuing Capabilities
Plasma and serum proteome profiling have become central to biomarker discovery for medical research. The advent of high-throughput plasma proteomics pipelines has enabled the generation of massive datasets. However, biomarker discovery is frequently compromised by sample contamination, primarily from erythrocytes, platelets, and coagulation factors. Such contamination can lead to the false identification of contaminants as biomarkers in over 50% of studies or obscure genuine biomarkers due to contamination-induced variability. Currently, no tools are available to salvage such compromised data, and the default approach is often to discard the affected samples. To address this gap, we introduce CAT-APP ( C ontamination A nalysis and T empering-An A utomated Online Platform for P lasma P roteomics). CAT-APP tackles contamination through three key modules: multi-dimensional contamination assessment and adaptive contamination indexing, mathematical model-based contamination tempering, and data recovery evaluation with visualization. We applied CAT-APP to 28 independent plasma proteomics datasets and found that 82% exhibited contamination issues. CAT-APP markedly improved data quality by removing false-positive biomarkers introduced by contamination and restoring true biological signals that were previously obscured in representative datasets. To promote widespread adoption, we provide CAT-APP as an freely accessible, user-friendly, and robust web platform at https://www.bloodecosystem.com/tools/CAT-APP/ .
- Open Access
- 5 May 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (5) , 112481
MTHFD2 reprograms macrophage polarization by inhibiting PTEN
- 5 May 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (5) , 112481
Open AccessMTHFD2 reprograms macrophage polarization by inhibiting PTEN
- Open Access
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100708
In vitro and in vivo evaluation of virus-induced innate immunity in mouse
- 1 September 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (3) , 100708
Open AccessIn vitro and in vivo evaluation of virus-induced innate immunity in mouse